New Stock News | Yimufen Biotechnology Resubmits Application to Hong Kong Stock Exchange

According to a disclosure by the Hong Kong Stock Exchange on August 18, Shenzhen Yimufeng Biotechnology Co., Ltd. - B (referred to as "Yimufeng Biotechnology") has once again submitted an application to the main board of the Hong Kong Stock Exchange, with Huatai International as the sole sponsor. According to the prospectus, the company was founded in 2020 and is an innovative cell therapy company focused on the discovery, development, manufacturing, and commercialization of chimeric antigen receptor (CAR) T cell therapies, utilizing a dual-engine approach of both in vitro and in vivo CAR-T cell therapies to treat solid tumors, hematologic malignancies, and autoimmune diseases.